MED: Board Resolution on approving the dossier of registration for the public offering
With risks from interruption of the medical ingredient supply chain and losses in the hospital channel, the Vietnamese pharma industry experienced a topsy-turvy first half of 2021, with potential growth set to focus on mergers and acquisitions.